At a glance
- Originator Pfizer
- Mechanism of Action Endothelin A receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 21 Jun 2000 Warner-Lambert has merged with Pfizer
- 04 Jul 1997 Preclinical development for Vascular disorders in USA (Unknown route)
- 16 May 1997 New profile